News Good news for Amgen as Repatha reverses atherosclerosis Encouraging data could point to strong outcomes data, expected next year
News NICE rejects Amgen's Kyprolis in multiple myeloma NICE rejects drug despite efficacy and quality of life evidence.
News Pfizer's hopes for cholesterol blockbuster dashed Sales of cancer drug Ibrance also fall short of expectations.
News EU regulator begins publishing detailed study data European Medicines Agency proactively publishes clinical study reports for first time.
News Amjevita, first Humira biosimilar approved – but no launch y... Amgen's biosimilar is ready to go, but AbbVie believes it can delay until 2022
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
